But abstinence is usually a higher bar akin to demanding that an antidepressant make full remission of depression or that an analgesic entirely eliminate discomfort. Recognizing this limitation, the FDA encourages builders of opioid2 and stimulant3 use disorder prescription drugs to discuss with FDA alternative strategies to evaluate adjustments in https://maps.app.goo.gl/ySf3nrmpAxXCtFGHA